Here are five notes:
1. The phase 3 UNITI-2 study, sponsored by Janssen Research & Development, focused on examining the efficacy and safety of STELARA, is a monoclonal antibody that targets interleukin-12 and IL-23 cytokines.
2. Patients participating in the study received a single intravenous infusion of placebo, STELARA 130 mg or STELARA ~6 mg/kg.
3. At week six, 52 percent of patients receiving STELARA 130 mg and 56 percent of patients receiving STELARA ~6 mg/kg achieved clinical response.
4. At week eight, 47 percent and 58 percent of patients receiving STELARA 130 mg and STELARA ~6 mg/kg respectively achieved clinical response, compared with 32 percent of patients receiving placebo.
5. STELARA also resulted in statistically significant improvements in the Inflammatory Bowel Disease Questionnaire, a health-related quality of life measure for IBD patients.
More articles on GI/endoscopy:
3 GI physicians in the news – Oct. 16, 2015
ACG elects Dr. Kenneth DeVault president: 5 things to know
5 most-read GI/endoscopy stories – Week of Oct 12 to Oct. 16
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
